Hydroxychloroquine Retinopathy: Screening, Risk Stratification, and Prevention
Hydroxychloroquine (HCQ) is widely prescribed in the United Kingdom for autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis. Although generally safe, long-term use is associated with a risk of retinal toxicity, which may result in irreversible visual impairment. Hydroxychloroquine retinopathy (HCR) is often asymptomatic in its early stages, making structured screening programmes essential. In response to emerging evidence of higher-than-previously recognised prevalence, the Royal College of Ophthalmologists has developed national guidelines for monitoring. This article reviews the pathophysiology, risk factors, clinical features, UK-based screening recommendations, and management strategies for HCR, with emphasis on prevention and early detection.
